NEW YORK, April 15 (GenomeWeb News) - Agilent Technologies today announced that researchers at Peter MacCallum Cancer Center of Melbourne, Australia, will use its comparative genomic-hybridization microarray products in a three-year cancer study.
The researchers will use the human CGH arrays to study mesothelioma, a cancer found in the lining of the chest, the abdominal cavity and around the heart, usually caused by exposure to asbestos.
Financial details were not disclosed.